Literature DB >> 11523528

Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.

F J Schmitz, M Boos, S Mayer, D Hafner, H Jagusch, J Verhoef, A C Fluit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11523528      PMCID： PMC90713          DOI： 10.1128/AAC.45.9.2666-2667.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.

Authors:  X Zhao; J Y Wang; C Xu; Y Dong; J Zhou; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

5.  Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages.

Authors:  B Y Zhao; R Pine; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

6.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.

Authors:  A Kitamura; K Hoshino; Y Kimura; I Hayakawa; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

8.  Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.

Authors:  T Ito; M Matsumoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
  8 in total
  4 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae.

Authors:  Glen T Hansen; Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 3.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.